报价延迟最少15分钟:2025/09/12 00:05 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
397.37 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
14.06/19.63
|
|
企业价值
101.28B
|
| 资产负债 |
|
每股账面净值
66.99
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
11.02B
|
|
每股收益
37.65
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/12 00:05 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
